Median PFS in patients treated with temsirolimus/bevacizumab ( n = @ ) versus IFN/bevacizumab ( n = @ ) was @ and @ months , respectively ( hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @ to @ ; P = @ ) .